[{"address1": "1210-1220 Washington St.", "address2": "Suite 210", "city": "Newton", "state": "MA", "zip": "02465", "country": "United States", "phone": "617 344 4190", "website": "https://acumenpharm.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.", "fullTimeEmployees": 61, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel J. O'Connell M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 1047590, "exercisedValue": 0, "unexercisedValue": 1034567}, {"maxAge": 1, "name": "Dr. James  Doherty Ph.D.", "age": 56, "title": "President & Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 730785, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Zuga", "title": "CFO & Chief Business Officer", "fiscalYear": 2024, "totalPay": 703157, "exercisedValue": 0, "unexercisedValue": 254161}, {"maxAge": 1, "name": "Dr. Grant A. Krafft Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "totalPay": 42000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caleb E. Finch Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William L. Klein Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Russell  Barton M.S.", "age": 66, "title": "Chief Operating Officer", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 223680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Carranza", "title": "Vice President, Finance & Accounting and Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alex  Braun M.B.A.", "title": "VP & Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Derek M. Meisner Esq., J.D.", "age": 53, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 752945, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.16, "open": 2.17, "dayLow": 2.09, "dayHigh": 2.175, "regularMarketPreviousClose": 2.16, "regularMarketOpen": 2.17, "regularMarketDayLow": 2.09, "regularMarketDayHigh": 2.175, "payoutRatio": 0.0, "beta": 0.248, "forwardPE": -1.2158719, "volume": 91917, "regularMarketVolume": 91917, "averageVolume": 279512, "averageVolume10days": 193040, "averageDailyVolume10Day": 193040, "bid": 1.52, "ask": 2.63, "bidSize": 2, "askSize": 2, "marketCap": 127809920, "fiftyTwoWeekLow": 0.855, "fiftyTwoWeekHigh": 2.46, "allTimeHigh": 26.98, "allTimeLow": 0.855, "fiftyDayAverage": 1.9792, "twoHundredDayAverage": 1.45507, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 32036926, "profitMargins": 0.0, "floatShares": 35610511, "sharesOutstanding": 60573425, "sharesShort": 568193, "sharesShortPriorMonth": 1318100, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.0094, "heldPercentInsiders": 0.070310004, "heldPercentInstitutions": 0.64735, "shortRatio": 3.71, "shortPercentOfFloat": 0.0126, "impliedSharesOutstanding": 60573425, "bookValue": 1.538, "priceToBook": 1.3719115, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -133351000, "trailingEps": -2.21, "forwardEps": -1.73538, "enterpriseToEbitda": -0.232, "52WeekChange": 0.23428571, "SandP52WeekChange": 0.17354333, "quoteType": "EQUITY", "currentPrice": 2.11, "targetHighPrice": 10.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.4, "targetMedianPrice": 6.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 126609000, "totalCashPerShare": 2.09, "ebitda": -138170000, "totalDebt": 30836000, "quickRatio": 5.799, "currentRatio": 6.019, "debtToEquity": 33.095, "returnOnAssets": -0.42226002, "returnOnEquity": -0.85929, "grossProfits": -118928000, "freeCashflow": -78959504, "operatingCashflow": -123657000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ABOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Acumen Pharmaceuticals, Inc.", "longName": "Acumen Pharmaceuticals, Inc.", "averageDailyVolume3Month": 279512, "fiftyTwoWeekLowChange": 1.2549999, "fiftyTwoWeekLowChangePercent": 1.467836, "fiftyTwoWeekRange": "0.855 - 2.46", "fiftyTwoWeekHighChange": -0.35000014, "fiftyTwoWeekHighChangePercent": -0.14227648, "fiftyTwoWeekChangePercent": 23.428572, "earningsTimestamp": 1762954200, "earningsTimestampStart": 1762954200, "earningsTimestampEnd": 1762954200, "earningsCallTimestampStart": 1762952400, "earningsCallTimestampEnd": 1762952400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.21, "epsForward": -1.73538, "epsCurrentYear": -2.28474, "priceEpsCurrentYear": -0.9235186, "fiftyDayAverageChange": 0.13079989, "fiftyDayAverageChangePercent": 0.06608725, "twoHundredDayAverageChange": 0.6549299, "twoHundredDayAverageChangePercent": 0.45010197, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-01", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": -2.31482, "regularMarketPrice": 2.11, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1625146200000, "postMarketChangePercent": -0.94786644, "postMarketPrice": 2.09, "postMarketChange": -0.01999998, "regularMarketChange": -0.0500002, "regularMarketDayRange": "2.09 - 2.175", "fullExchangeName": "NasdaqGS", "corporateActions": [], "postMarketTime": 1766787610, "regularMarketTime": 1766782800, "exchange": "NMS", "messageBoardId": "finmb_8539521", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "Acumen Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-12-27"}]